TNF-related apoptosis-inducing ligand (TRAIL) is a potent inducer of cell death in several cancer cells, but many cells are resistant to TRAIL. The mechanism that determines sensitivity to TRAIL-killing is still elusive. Here we report that deletion of TAK1 kinase greatly increased activation of caspase-3 and cell death after TRAIL stimulation in keratinocytes, fibroblasts and cancer cells. Although TAK1 kinase is involved in NF-kB pathway, ablation of NF-kB did not alter sensitivity to TRAIL. We found that TRAIL could induce accumulation of reactive oxygen species (ROS) when TAK1 was deleted. Furthermore, we found that TAK1 deletion induced TRAIL-dependent downregulation of cIAP, which enhanced activation of caspase-3. These results show that TAK1 deletion facilitates TRAIL-induced cell death by activating caspase through ROS and downregulation of cIAP. Thus, inhibition of TAK1 can be an effective approach to increase TRAIL sensitivity.
Introduction
TNF-related apoptosis inducing ligand (TRAIL) is a member of the TNF family cytokines that can selectively kill several cancer cells, whereas non-transformed cells are resistant to TRAIL (Takeda et al., 2007) . TRAIL initiates cell-death signaling through the binding of TRAIL to death receptor 4 (DR4) and death receptor 5 (DR5) (Ashkenazi, 2002; LeBlanc and Ashkenazi, 2003; Wang and El-Deiry, 2003) . TRAIL binding to its receptors leads to the assembly of Fas-associated death domain (FADD) and caspases-8 at the C-terminus of the receptors to form the death inducing signaling complex (DISC). Activation of caspase-8 in the DISC is then followed by the activation of executioner caspases, such as caspases-3. In TNF-induced signaling pathways, TNF not only initiates cell-death signaling but also upregulates anti-apoptotic genes such as cellular FLICEinhibitory protein (c-FLIP) through a transcription factor NF-kB (Wang et al., 1998; Micheau et al., 2001; Aggarwal, 2003; Hayden and Ghosh, 2008) . As this antiapoptotic pathway normally overrides the cell-death pathway in most cell types, TNF does not kill cells (Aggarwal, 2003) . Inhibition of NF-kB pathway increases the sensitivity to TNF-induced cell death (Karin and Lin, 2002) . In contrast to TNF, involvement of NF-kB in the TRAIL sensitivity has not been established. In several types of cells, TRAIL activates NF-kB resulting in up-regulation of anti-apoptotic genes such as Mcl-1 (Meng et al., 2007; Ricci et al., 2007; Kim et al., 2008b) and c-FLIP (Siegmund et al., 2001; Kim et al., 2002; Xiao et al., 2002) , which have been implicated in TRAIL resistance. In other reports, NF-kB signaling appears not to be critical for TRAIL resistance (Varfolomeev et al., 2005; Kurbanov et al., 2007) . Thus, involvement of NF-kB in TRAIL sensitivity is still undetermined. TAK1 kinase is a member of the mitogen activated protein kinase kinase kinase (MAPKKK) family and is activated by innate immune stimuli including bacterial components and proinflammatory cytokines such as IL-1 and TNF (Ninomiya-Tsuji et al., 1999; Sato et al., 2005; Chen et al., 2006) . Recently, Choo et al., 2006 had shown that TAK1 is important for blocking TRAILinduced cancer cell death. However, the mechanism of how TAK1 regulates TRAIL-killing is still elusive. TAK1 plays an essential role in innate immune signaling by activating both IKK-NF-kB and MAPK pathways. TAK1 is an indispensable intermediate of NF-kB activation. In addition to this well-established TAK1 pathway, we have recently identified that TAK1 modulates the levels of reactive oxygen species (ROS), which are important for preventing TNF-induced cell death in keratinocytes (Omori et al., 2006 (Omori et al., , 2008 . It has been reported that ROS plays an essential role in TNFinduced cell death (Ventura et al., 2004; Kamata et al., 2005; Chang et al., 2006) . We found that TAK1 is essential for preventing accumulation of TNF-induced ROS and subsequent activation of ROS-mediated death pathways (Omori et al., 2008) . Thus, TAK1 is involved in two pathways that potentially affect sensitivity to cell-death signaling; one is NF-kB pathway; and another is a pathway through ROS regulation. In this study, we investigated the mechanism by which TAK1 regulates sensitivity to TRAIL-induced cell death. We asked whether TAK1-NF-kB or TAK1-ROS pathway is involved in TRAIL sensitivity.
Results and discussion
TAK1 is essential for cell survival against TRAIL-induced cell death We investigated the role of TAK1 signaling in TRAILinduced cell death. We used wild-type and TAK1D/D mouse keratinocytes (Omori et al., 2006) and embryonic fibroblasts (MEFs) (Sato et al., 2005) to determine the essential role of TAK1 in TRAIL-killing pathway. Wildtype and TAK1D/D keratinocytes were isolated from the dorsal skin of TAK1-floxed (TAK1 flox/flox ) or epidermisspecific TAK1 deletion (K5-Cre TAK1 flox/flox ) mice, respectively. In this floxed TAK1 system, Cre recombinase catalyses the deletion of the TAK1 ATP binding site, amino acid 41-77, resulting in the generation of a truncated form of TAK1 (TAK1D) (Figure 1d , bottom panel). We treated wild-type and TAK1D/D keratinocytes with TRAIL and cell viability was determined. Although wild-type keratinocytes were completely resistant to TRAIL, TRAIL could induce cell death in TAK1D/D keratinocytes in a dose-dependent manner (Figure 1a ). To verify whether this cell death is associated with apoptosis, we examined annexin V binding ( Figure 1b ). TRAIL increased annexin V binding positive cells in TAK1D/D keratinocytes. To confirm whether this cell death is due to TAK1 deficiency, we generated TAK1restored TAK1D/D keratinocytes by infecting TAK1 expressing retrovirus and carried out the annexin V binding assay. Restoration of TAK1 completely inhibited TRAIL-induced apoptosis, suggesting that TAK1 ablation is the cause of hypersenisitivity to TRAIL ( Figure 1b ). We next asked whether this hypersensitivity to TRAIL is specific for keratinocytes, and we treated wild-type and TAK1D/D MEFs with TRAIL stimulation. The earlier study reported that TAK1 ablation does not increase sensitivity to TRAIL-induced cell death in MEFs (Choo et al., 2006) . However, we found that TRAIL also induced cell death in TAK1D/D MEFs, although the sensitivity to TRAIL-induced cell death is less compared with that in keratinocytes ( Figure 1c ). Our data suggest that TAK1 is essential for preventing TRAIL-induced cell death in non-transformed cells including keratinocytes and MEFs. TRAIL binding to TRAIL receptor initiates activation of the caspase cascade consisting of caspase-8 and caspase-3, which is the major pathway to TRAIL-induced cell death (Aggarwal, 2003) . Thus, we Figure 1d ). Thus, TAK1 prevents TRAIL-induced cell death through inhibiting caspase activation.
NF-kB does not contribute to cell survival in TRAIL-dependent cell death NF-kB is one of the major cell survival factors that upregulates a number of anti-apoptotic molecules including caspase inhibitors, c-FLIP, Mcl-1 and BclxL. TAK1 is the major upstream regulator of NF-kB in proinflammatory cytokine signaling pathways including TNF pathway (Takaesu et al., 2003; Shim et al., 2005) . It has been reported that TRAIL activates NF-kB in several cell types (Varfolomeev et al., 2005) . Therefore, one likely mechanism by which TAK1 prevents TRAILinduced cell death is that TAK1 activates NF-kB in response to TRAIL stimulation and promotes cell survival. The earlier report proposed that lack of NF-kB activation might be the cause of cell death in TAK1deficient cells (Choo et al., 2006) . However, we found that TNF but not TRAIL could activate TAK1 pathways including activation of NF-kB, JNK, and p38 (Supplementary Figure S1 ), suggesting that NF-kB may not be the major pathway to determine TRAIL sensitivity. To further examine whether the NF-kB pathway contributes to TRAIL resistance in keratinocytes, we generated wild-type keratinocytes ectopically expressing a super-repressor of IkB (IkBDN) that lacks the N-terminal region including the phosphorylation sites for its degradation (Brockman et al., 1995) . In these cells, TNF-induced NF-kB activation was completely abolished (Figure 2a ). Furthermore, the basal level of NF-kB was also significantly reduced in the IkBDN expressing keratinocytes. Therefore, the IkBDN expressing keratinocytes may be considered as NF-kBdeficient cells. We examined the susceptibility of these cells to TRAIL-killing. We found that abrogation of NF-kB pathway did not sensitize cells to TRAIL ( Figure 2b ). In contrast, TNF could induce cell death in the IkBDN-expressing keratinocytes to some extent Figure 2b ) as we showed earlier (Omori et al., 2008) , which is consistent with earlier studies that used IKK deficient MEFs (Li et al., 1999; Rudolph et al., 2000) . To further examine whether downregulation of NF-kB does not cause hypersensitivity to TRAIL-induced cell death, we utilized IKKg/NEMO knockout MEFs (Makris et al., 2000) and examined the TRAIL sensitivity. IKKg/NEMO knockout MEFs were sensitive to TNFinduced cell death as reported earlier (Rudolph et al., 2000) (Figure 2d ), however, we found that they were completely resistant to TRAIL-induced cell death ( Figure 2c ). These results show that NF-kB pathway is not the major pathway to prevent TRAIL-induced cell death. Therefore, TAK1-mediated prevention of TRAIL-induced cell death should be through non-NF-kB mechanisms.
Reactive oxygen species were accumulated upon TRAIL stimulation in TAK1 deficient keratinocytes and cancer cells Apoptosis is induced by activation of the caspase cascade and it has been known that ROS facilitate this apoptotic signaling (Chang et al., 2006) . Moreover, we have recently reported that TAK1 deficiency causes increased ROS in TNF-treated TAK1-deficient cells (Omori et al., 2008) . Therefore, we speculated that TRAIL might increase ROS in TAK1-deficient cells, and that TAK1-dependent ROS regulation might contribute to TRAIL sensitivity. We examined the level of ROS in TRAIL-and TNF-treated keratinocytes (Figure 3a ). We found that ROS were increased in TAK1D/D but not wild-type keratinocytes on both TNF and TRAIL stimulation. TNF greatly increased the level TAK1 regulates TRAIL-killing S Morioka et al of ROS within 3 h after stimulation. TRAIL was a less potent inducer of ROS compared with TNF. TRAIL did not increase the level of ROS at 3 h, but it was increased 6 h after stimulation. We next asked whether this increased ROS causes hypersensitivity to TRAIL. We pretreated cells with the antioxidant butylated hydroxyanisole (BHA) and stimulated cells with TRAIL. BHA treatment completely blocked TRAILinduced cell death (Figure 3b ) and annexin V binding (Figure 3c ). TRAIL-induced caspase-3 activation was also inhibited by BHA treatment (Figure 3d ). These results suggest that TRAIL increased ROS when TAK1 is deleted, which promotes apoptotic signaling pathway. TRAIL treatment is one of the most anticipated anticancer therapies. However, many cancer cells are TRAIL resistant. We postulate that downregulation of TAK1 can increase in sensitivity to TRAIL through ROS in cancer cells. We downregulated TAK1 expres-sion in human osteosarcoma Saos2 cells and HeLa cells by transient transfection of a siRNA and also by stable transfection of a shRNA targeted against TAK1, and examined for ROS accumulation and TRAIL-induced cell death (Figure 4 ). Saos2 cells were resistant to TRAIL-induced cell death, whereas HeLa cells were moderately sensitive to TRAIL-induced cell death. We treated Saos2 and HeLa cells with 100 ng/ml and 10 ng/ml TRAIL, respectively, which did not kill control cells with normal TAK1 expression ( Figure 4c ). We found that TAK1 knockdown greatly increased TRAILinduced ROS accumulation (Figure 4b ) and concomitantly induced cell death in both Saos2 and HeLa cells (Figure 4c ). We used two different siRNA or shRNA targeted sequences of TAK1 and obtained the similar results. To further assess whether this cell death is through the same mechanism as that in keratinocytes, we examined activation of caspase-3 (Figures 4d and e ).
Figure 4 TAK1 down regulation accumulates ROS and sensitizes cancer cells to TRAIL. (a) TAK1 or non-targeting (Ctrl) siRNA was transfected into Saos2 or HeLa cells using the electroporation method, and cells were incubated for 3 days (left and middle panels). Saos2 cells were infected a retrovirus expressing TAK1 shRNA or control vector, and infected cells were selected (right panels). The amounts of TAK1 were analysed by immunoblots, and a-tubulin or b-actin was used as a loading control. (b) Non-targeting (Ctrl) and TAK1 siRNA transfected Saos2 cells were stimulated with TRAIL (100 ng/ml) for 18 h. Non-targeting (control) and TAK1 siRNA transfected HeLa cells were stimulated with TRAIL (10 ng/ml) for 6 h. Subsequently, cells were incubated with CM-H 2 DCFDA for 30 min, and 3-5 randomly selected areas were photographed with the same exposure time. The images were processed using the fixed threshold in all samples in each experiment, and 41000 cells were counted for each sample. (c) Saos2 cells were stimulated with TRAIL (100 ng/ml) for 24 h. HeLa cells were stimulated with TRAIL (10 ng/ml) for 18 h. Live cells were measured by crystal violet staining. Data are the means and SD of three samples. (d, e) Activation of caspase-3 was analysed by immunoblots in TAK1 siRNA transiently transfected (d) or TAK1 shRNA stably infected (e) Saos2 cells. a-tubulin was used as a loading control.
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Ablation of TAK1 downregulates cIAP
We next attempted to determine the mechanism of how TRAIL-induced ROS facilitates activation of caspases in TAK1 deficient cells. As TRAIL activates caspase through DISC, we speculated that ROS might enhance activation of DISC. Two pathways have been known to enhance DISC activation. One is c-FILP downregulation, which is through inhibition of NF-kB (Chang et al., 2006) . Recently, a new pathway to activate DISC, which is independent of inhibition of NF-kB, has been shown (Wang et al., 2008) . In this pathway, smac, an inhibitor of IAP, induces degradation of cIAPs which results in activation of DISC-induced caspases (Petersen et al., 2007; Vince et al., 2007) . Smac mimetics, small molecules mimicking smac binding to IAP, induce DISC-dependent apoptosis through this pathway (Petersen et al., 2007; Vince et al., 2007; Wang et al., 2008) . As NF-kB is not involved in TAK1 deletioninduced TRAIL sensitivity as described above, we speculated that TAK1 deletion might facilitate this smac-cIAP pathway. We treated cells with TNF and TRAIL, and examined the levels of cIAPs in wild-type and TAK1D/D keratinocytes (Figure 5a ). The smac mimetic was used as a positive control. We found that the amount of cIAP2 decreased upon treatment of TNF and TRAIL in both wild-type and TAK1D/D keratinocytes, and that the reduction was augmented by TAK1 deletion. At 6-12 h post-TNF treatment and at 12-24 h post-TRAIL treatment, the amount of cIAP2 was greatly diminished in TAK1D/D keratinocytes. This decreased cIAP2 level was correlated with activation of caspase-3 (Figure 5a ). The smac mimetic alone did not induce activation of caspase-3 in keratinocytes, which suggests that cIAP degradation alone is not sufficient to induce apoptosis in keratinocyte. This is consistent with the earlier reported effect of smac mimetics in several cell types (Petersen et al., 2007; Vince et al., 2007; Wang et al., 2008) . Both DISC activation and cIAP degradation are required to trigger apoptosis. We note that we were not able to detect cIAP1 in keratinocytes. To examine whether ROS mediate this decrease of cIAP2, we treated keratinocytes with the antioxidants BHA and L-N-acetylcysteine (L-NAC). BHA could inhibit TNFand TRAIL-induced reduction of cIAP2 (Figure 5b ). L-NAC could also block TNF-induced reduction of cIAP2 and activation of caspase-3 (Supplementary Figure S2) . These results suggest that ablation of TAK1 downregulates cIAP in response to TNF and TRAIL treatment, which facilitates caspase activation.
Choo et al. had earlier reported that TAK1 knockdown sensitizes HeLa cells to TRAIL-induced cell death, and discussed that impaired activation of NF-kB might be the cause of this hypersensitivity (Choo et al., 2006) . However, here we show that TAK1 but not NF-kB regulates TRAIL sensitivity. We further show that TRAIL induces ROS accumulation and cIAP degradation in TAK1 deficient keratinocytes. Our results showed a new mechanism that determines sensitivity to TRAIL. TAK1 regulates TRAIL sensitivity through the ROS-cIAP pathway.
Our findings raise several important questions. One is the mechanism by which ROS induce cIAP degradation. We speculate that ROS damage mitochondria resulting in mitochondrial permeabilization, which could release smac, a major inducer of cIAP degradation (Wang et al., 2008) . Another important question is the mechanism by which TAK1 regulates ROS. We have shown that Figure 5 TRAIL downregulates cIAP in TAK1 deficient keratinocytes. (a) Wild-type ( þ / þ ) and TAK1D/D keratinocytes were stimulated with TNF (20 ng/ml) or TRAIL (100 ng/ml). Smac mimetic (SM) (1 mM) was used as a control. cIAP and caspase-3 were detected by immunobots. b-actin was used as a loading control. (b) TAK1D/D keratinocytes was pretreated with or without 100 mM BHA for 1 h and stimulated with TNF (20 ng/ml) or TRAIL (100 ng/ml) or left unstimulated (BHA alone). cIAP was detected by immunobots. b-actin was used as a loading control. recently reported that TAK1 is activated by TRAIL in human breast epithelial cells, and that TAK1 activation of AMP-activated protein kinase is involved in TRAIL sensitivity (Herrero-Martin et al., 2009) . The difference in TAK1 activation by TRAIL may be due to cell-type difference. In regard to ROS regulation, we have recently reported that the basal level of c-Jun is regulated by TAK1, which is critically involved in ROS metabolism (Omori et al., 2008) . Furthermore, we have recently observed that the basal levels of several redox enzymes including catalase, NAD(P)H: quinone oxidoreductase 1 (NQO1) and glutathione S-transferases were downregulated in TAK1-deficient cells (SM, EO, RK-S and JN-T unpublished observation).
These suggest that TAK1 modulates redox enzymes possibly through c-Jun under basal conditions, which prevents accumulation of ROS after TRAIL stimulation. We propose that the basal activity of TAK1 is important for determination of TRAIL sensitivity. In some cell types, TAK1 may be further activated by TRAIL and prevents accumulation of ROS. TRAIL can selectively kill several cancer cells but not the majority of normal cells. Therefore, TRAIL is one of the most anticipated anti-cancer drugs (Ashkenazi, 2002; Reed, 2006; Takeda et al., 2007) . However, some cancer cells are resistant to TRAIL treatment. A number of trials have been conducted to sensitize these cancer cells to TRAIL-killing (Kim et al., 2008b) . We here show that deletion of TAK1 effectively sensitizes cells to TRAIL-killing even in non-transformed keratinocytes and fibroblasts, whereas NF-kB deletion is not capable of sensitizing those cells to TRAIL-killing. This raises the possibility that a combination of inhibition of TAK1 and the TRAIL treatment could effectively kill cancer cells, although this combination may kill normal cells. In summary, our finding provides a new strategy to sensitize cells to TRAIL. The TAK1-ROS-cIAP degradation axis may be a new target for cancer therapy.
Materials and methods

Cells
Wild-type and TAK1D/D keratinocytes were isolated from TAK1 flox/flox , K5-Cre TAK1 flox/flox mice described earlier and cultured as described earlier (Omori et al., 2006) . Wild-type and TAK1D/D MEFs were gifts from Dr Akira, Osaka University (Sato et al., 2005) . IKKgÀ/À MEFs were gifts from Dr Karin, University of San Diego (Makris et al., 2000) . MEFs, 293 cells, Saos2 and HeLa cells were cultured in DMEM with 10% bovine growth serum (Hyclone, Logan, UT, USA), and penicillin-streptomycin at 37 1C in 5% CO 2 .
Reagents TRAIL (human recombinant; Peprotech, Rocky Hill, NJ, USA) and TNFa (human recombinant; Roche, Basel, Switzerland) were used. Smac mimetic was a gift from Dr Xiaodong Wang, University of Texas Southwestern Medical Center at Dallas (Li et al., 2004) . Butylated hydroxy-anisole (BHA) and L-N-acetylcysteine (L-NAC) were purchased from Sigma, St Louis, MO, USA and Calbiochem, San Diego, CA, USA, respectively. Polyclonal antibodies used were TAK1 described earlier (Ninomiya-Tsuji et al., 1999) , JNK1 (FL; Santa Cruz, Santa Cruz, CA USA), p65 (F-6; Santa Cruz), caspase-3 (Cell Signaling, Boston, MA, USA), phospho-p38 (Thr-180/Tyr-182; Cell Signaling), and p-38 (N-20; Santa Cruz). Monoclonal antibodies were tubulin (Santa Cruz), bactin (Sigma), IkBa (H-4; Santa Cruz), phospho-JNK (Thr-183/ Tyr-185; Cell signaling) and cIAP (R&D Systems, Minneapolis, MN, USA).
Plasmids
Retroviral vector for TAK1 (pMxpuro-TAK1) was described earlier (Kim et al., 2008a) . Retroviral vector for IkBDN (pQCXIP-IkBDN) was generated by inserting IkBDN cDNA into retroviral vector pQCXIP (Clontech, Mountain View, CA, USA). IkBDN cDNA was a gift from Dr D. Ballard, Vanderbilt University (Brockman et al., 1995) . TAK1 siRNA target sequence corresponded to nucleotides 88-106 of the TAK1 cording region was used to generate a retrovirus vector expressing shRNA against TAK1. The region containing the TAK1 shRNA in the BS/H1 vector for TAK1 siRNA (Kajino et al., 2007) was subcloned into pSUPERRetro vector (OligoEngine, Seattle, WA, USA).
Cytotoxicity assay
The viable adherent cells were fixed with 10% formalin and stained with 0.1% crystal violet. The stain was solubilized by adding 50% ethanol containing 50 mM sodium citrate, and the absorbance of each plate was determined at 595 nm.
Electrophoresis mobility shift assay (EMSA)
The binding reaction contained radiolabeled 32 P-NF-kB oligonucleotide probe (Promega, Madison, WI, USA), 10 mg cell extracts, 4% glycerol, 1 mM MgCl 2 , 0.5 mM EDTA, 0.5 mM DTT, 50 mM NaCl, 10 mM Tris-HCl (pH 7.5), 500 ng of poly (dI-dC) (GE Healthcare, Milwaukee, WI, USA), and 10 mg of bovine serum albumin to a final concentration of 15 ml. The reaction mixture were incubated at 25 1C for 30 min, separated by 5% (w/v) polyacrylamide gel, and visualized by autoradiography.
Immunoblotting
Whole-cell extracts were prepared using a lysis buffer containing 20 mM HEPES (pH 7.4), 150 mM NaCl, 12.5 mM b-glycerophosphate, 1.5 mM MgCl 2 , 2mM EGTA, 10 mM NaF, 2 mM DTT, 1 mM Na 3 VO 4 , 1 mM phenylmethylsulfonyl fluoride, 20 mM aprotinin, 0.5% Triton X-100. Cell extracts were resolved on SDS-PAGE and transferred to Hypond-P membranes (GE Healthcare). The membranes were immunoblotted with various antibodies, and the bound antibodies were visualized with horseradish peroxidase-conjugated antibodies against rabbit or mouse IgG using the ECL western blotting system (GE Healthcare).
Retroviral infection
EcoPack 293 cells (BD Biosciences, Franklin Lakes, NJ, USA) were transiently transfected with pQCXIP-IkBDN. After 48 h culture, growth medium containing the retrovirus was collected and filtered with 0.45 mm cellulose acetate membrane to remove packaging cells. Keratinocytes were incubated with the collected virus-containing medium with 8 mg/ml polybrane for 24 h. Uninfected cells were removed by puromycin selection. GP-293 cells (BD Biosciences) were transiently transfected with pSUPERRetro-TAK1shRNA. After 48 h culture, growth medium containing the retrovirus was TAK1 regulates TRAIL-killing S Morioka et al collected and filtered with 0.45 mm cellulose acetate membrane to remove packaging cells. Saos2 or HeLa cells were incubated with the collected virus-containing medium with 8 mg/ml polybrane for 24 h. Uninfected cells were removed by puromycin selection.
Annexin V-binding assay
To determine apoptotic cells, Annexin V-Alexa Fluor 488 binding was carried out according to the manufacturer's protocol (Invitrogen, San Diego, CA USA), and fluorescence was detected with fluorescent microscope (Olympus, Center Valley, PA, USA).
ROS measurement
Keratinocytes were stimulated with TRAIL and incubated with 10 mM CM-H 2 DCFDA (Invitrogen) for 30 min at 37 1C, harvested and analysed by flow cytometry or fluorescence was detected by microscope.
Transient siRNA system TAK1 and non-targeting control siRNAs were obtained from Dharmacon, Lafayette, CO, USA (TAK1 siRNA, 5 0 -GAGU GAAUCUGGACGUUUA-3 0 ; Non-targeting siRNA#1). SAOS2 or HeLa cells were tripsinized and collected. Cells were sustained in OPTI-MEM medium (Invitrogen) containing 1 mM siRNA oligos and subjected to electroporation using Gene Pulser Xcell (Bio-Rad, Hercules, CA, USA).
